Compare UNTY & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNTY | LYEL |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.6M | 556.1M |
| IPO Year | 2014 | 2021 |
| Metric | UNTY | LYEL |
|---|---|---|
| Price | $51.75 | $19.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $65.00 | $30.60 |
| AVG Volume (30 Days) | 42.6K | ★ 75.8K |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ 39.66 | N/A |
| EPS | ★ 5.67 | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $12.14 | N/A |
| Revenue Next Year | $9.56 | $8,712.13 |
| P/E Ratio | $9.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $41.67 | $0.39 |
| 52 Week High | $57.30 | $45.00 |
| Indicator | UNTY | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 38.23 |
| Support Level | $50.54 | $16.20 |
| Resistance Level | $53.61 | $26.89 |
| Average True Range (ATR) | 1.57 | 1.61 |
| MACD | -0.27 | -0.41 |
| Stochastic Oscillator | 28.36 | 4.51 |
Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. The Company has elected to become a financial holding company pursuant to regulations of the Board of Governors of the Federal Reserve System (the FRB). The Company's primary business is ownership and supervision of the Bank. The Company and the Bank derive a majority of their revenue from net interest income (i.e., the difference between the interest received on loans and securities and the interest paid on deposits and borrowings). The Company, through the Bank, conducts a traditional and community-oriented commercial banking business and services, personal and business checking accounts, time deposits, money market accounts, savings accounts, credit cards, automated teller service, and others.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.